This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

This study has been completed.
Information provided by:
Ionis Pharmaceuticals, Inc. Identifier:
First received: June 25, 2003
Last updated: October 15, 2007
Last verified: October 2007
This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.

Condition Intervention Phase
Ulcerative Colitis Drug: Alicaforsen Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: ISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)

Resource links provided by NLM:

Further study details as provided by Ionis Pharmaceuticals, Inc.:


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

Patients must meet the following criteria at screening to be eligible for enrollment:

  • Age greater than or equal to 18 years
  • Diagnosis of ulcerative colitis of at least 6 months duration
  • Current left-sided flare, defined as activity in the colon 5-50 cm from the anal verge, extending at least 15 cm proximal to the anal verge and confirmed by endoscopic evaluation within 14 days of baseline visit.
  • Baseline DAI score of 4-10 including abnormal endoscopic score
  • On at least one or more of the following treatments for ulcerative colitis prior to baseline visit:

    1. Stable background oral mesalamine therapy for greater than or equal to 30 days, and/or
    2. Stable background mercaptopurine for greater than or equal to 60 days prior to baseline, and/or
    3. Stable azathiprine therapy for greater than or equal to 60 days prior to baseline
  • Written informed consent prior to performing screening evaluations.

Exclusion criteria

Patients who meet any of the following criteria at screening are not eligible for enrollment:

  • Bowel stricture, toxic megacolon, colonic dysplasia, adenoma or carcinoma
  • Uncontrolled hematologic, renal, hepatic, metabolic, psychiatric, CNS, pulmonary or cardiovascular disease, or sufficient level of disease that could interfere with the patient's ability to comply with protocol participation
  • Enteric pathogens or presence of Clostridium difficile toxin in stool
  • History of colon resection
  • Major surgical procedure within one month of baseline visit
  • Steroid or mesalamine enema within 14 days of baseline visit
  • Systemic steroids (including ACTH) within 30 days of baseline visit
  • Tumor necrosis factor-alpha (TNF-α) inhibitor treatment within 90 days of baseline visit
  • Non-steroidal anti-inflammatory agents (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors, within 14 days of baseline visit
  • Methotrexate, cyclosporin or thalidomide within 90 days of baseline visit
  • Any active infection currently requiring treatment
  • Malignancy within 5 years except for squamous cell or basal cell cancers of the skin
  • Current infectious, ischemic, or immunological disease with gastrointestinal involvement
  • ISIS 2302 treatment within 12 months of baseline visit
  • History of allergy to mesalamine
  • Treatment with an investigational or off-label drug within 90 days of screening or currently in long-term follow up for another investigational treatment protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00063414

United States, Illinois
Chicago, Illinois, United States
Sponsors and Collaborators
Ionis Pharmaceuticals, Inc.
  More Information Identifier: NCT00063414     History of Changes
Other Study ID Numbers: ISIS 2302-CS22
Study First Received: June 25, 2003
Last Updated: October 15, 2007

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 17, 2017